In:
Medical Principles and Practice, S. Karger AG, Vol. 20, No. 1 ( 2011), p. 23-28
Abstract:
〈 i 〉 Objective: 〈 /i 〉 The aim of this prospective study was to investigate the effect of LT4 suppression therapy on plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen and plasminogen activator inhibitor-1 (PAI-1) levels in benign thyroid nodules. We also compared hyperthyroid patients and healthy controls. 〈 i 〉 Subjects and Methods: 〈 /i 〉 Twenty premenopausal women with benign thyroid nodules were given LT4 suppression therapy for 1 year. Plasma TAFI and PAI-1 antigen levels were measured at baseline and after LT4 suppression treatment. The endogenous hyperthyroid group was composed of 19 premenopausal females with newly diagnosed endogenous hyperthyroidism. Eighteen age-matched euthyroid healthy premenopausal women were enrolled as the control group. 〈 i 〉 Results: 〈 /i 〉 TAFI antigen levels decreased after LT4 suppression treatment; however, the difference was not statistically significant (p = 0.057). LT4 treatment resulted in a nonsignificant increase in PAI-1 levels. Patients with endogenous hyperthyroidism had decreased levels of TAFI antigen and increased levels of PAI-1 antigen (p 〈 0.05). There was a negative correlation between the FT 〈 sub 〉 4 〈 /sub 〉 and TAFI antigen levels. Serum TSH was positively correlated with the plasma levels of TAFI antigen. 〈 i 〉 Conclusion: 〈 /i 〉 LT4 suppression therapy for benign thyroid nodules did not result in a significant decrease in TAFI antigen levels in premenopausal women, but endogenous hyperthyroidism was associated with significantly decreased levels of TAFI antigen.
Type of Medium:
Online Resource
ISSN:
1011-7571
,
1423-0151
Language:
English
Publisher:
S. Karger AG
Publication Date:
2011
detail.hit.zdb_id:
1482963-0
Permalink
